RecruitingOesophageal Squamous Cell Carcinoma
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.
Sponsor: Merck Sharp & Dohme LLC
You may qualify if…
- ✓ Has a histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- ✓ Has disease progression after 1 or 2 prior lines of systemic therapy for unresectable locally advanced or metastatic ESCC
- ✓ Has measurable disease
- ✓ If infected with human immunodeficiency virus (HIV), has well-controlled HIV on antiretroviral therapy
- ✓ Has adequate organ function
You may not qualify if…
- ✕ Has histologically or cytologically confirmed adenocarcinoma or adenosquamous carcinoma subtype
- ✕ Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
- ✕ Has clinically significant corneal disease
- ✕ Has any of the following within 6 months before screening: cerebrovascular accident, transient ischemic attack, other arterial thromboembolic event
- ✕ If infected with HIV, has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- ✕ Has uncontrolled or significant cardiovascular disease
- ✕ Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- ✕ Has known active central nervous system metastases and/or carcinomatous meningitis
Where it's recruiting
Pennsylvania
Pittsburgh
Source: ClinicalTrials.gov · NCT07405151 · last updated 2026-07-30